Eins in activated astrocytes which may be transferred to manage neuronal function and plasticity. Summary/Conclusion: Our acquiring will probably be helpful to elucidate the pathophysiological functions of astrocytederived exosomes in regulating neuronal networks and give new insights into the diagnostics and therapeutics of inflammatory illnesses. Funding: NIH 1R01AG054672, 1R56AG057469 and 1RF1AG054199 (TI), 5R24HDISEV2019 ABSTRACT BOOKSaturday Poster Session PS01: Engineering and Loading EVs Chairs: Hang Hubert Yin; Antonella Bongiovanni Location: Level three, Hall A 15:006:PS01.Targeting prostate cancer by way of PSMA-peptide decorated exosomemimetics Maja Severic, Guanglong Ma, Hatem Hassan, Sara Pereira, Calvin Cheung and Wafa AL-Jamal Queen’s University Belfast, Belfast, UKIntroduction: Prostate cancer (Computer) is definitely the most common kind of cancer along with the second cause of death in men worldwide. A selection of productive anticancer drugs happen to be employed to treat advanced Pc, on the other hand, their systemic toxicity has restricted their clinical use. Therefore, there’s an unmet need to create novel strategies to deliver cancer therapeutics to Computer tissues. Exosomes are nanosized, cellderived vesicles that carry proteins and RNAs for intercellular communication. They could also deliver their cargo across the plasma membrane and delay premature drug transformation and elimination. Exosomes have shown an intrinsic homing ability to a wide range of cells. In addition, a brand new approach has been proposed to combine the intrinsic homing capacity of exosomes with active targeting to boost their tumour accumulation. In the present operate, we report the development of novel prostate-specific membrane antigen (PSMA)targeted exosome-mimetics (EMs) for advanced Computer. Solutions: Stably transfected PSMA-peptide expressing monocytes U937 cell line was established. PSMA-targeted EMs have been prepared by serial extrusion on the transfected U937 monocytes. The PSMA-targeted EMs were characterized by dynamic light scattering, nanoparticle tracking evaluation, transmission electron microscopy, bicinchoninic acid assay and western blotting. Furthermore, the binding with the PSMA-targeted EMs for the recombinant human PSMA protein was confirmed by ELISA. Their drug loading capability was assessed by loading doxorubicin and its derivatives. Next, in vivo biodistribution and safety studies of targeted EMs have been carried out in C4-2B and PC3tumour-bearing mice. Final results: The engineered EMs exhibited higher protein yield, very good drug loading and exosome markersexpression. The expression of PSMA targeting peptide and its binding to PSMA receptors was confirmed in vitro. Ultimately, productive tumour accumulation of PSMA-targeted EMs was achieved in vivo using the absence of in vivo toxicity. Summary/Conclusion: Our engineered PSMA-targeted EMs, could offer a promising drug delivery program for Pc, depending on its drug loading capacity, tumour targeting and security in vivo. Funding: Rosetrees Trust studentship (A1108), PCUK (CDF-12-002 Fellowship) and EPSRC (EP/BTLA/CD272 Proteins Gene ID M008657/1).PS01.Enhanced loading of plasma-derived extracellular vesicles to encapsulate CD73 Proteins Accession antitumour miRNAs Margherita A. C. Pomattoa, Benedetta Bussolatib, Sergio D’Anticoc, Sara Ghiottoc, Ciro Tettad, Maria Felice Brizzia and Giovanni Camussia Division of Medical Sciences, University of Turin, Turin, Italy; Division of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy; cBlood Bank, A.O.U. Cittdella Salute e della Scienza, Turin, Italy; dUnicy.
